Home / Publications / Pain Research Forum / Papers of the Week / At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study.
At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study.
It is critical to assess who is being treated with a new marketed drug like esketamine to understand how it is used in the real-world setting and the effects of the medication.
